Dublin, June 26, 2023 (GLOBE NEWSWIRE) -- The "Rare Diseases Market Report 2023-2033" report has been added to ResearchAndMarkets.com's offering.
Overall world revenue for the Rare Diseases Market will surpass US$205 billion in 2023. The report predicts strong revenue growth through to 2033 and identifies which organizations hold the greatest potential.
The Rare Diseases Market Report 2023-2033 will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
There are unmet requirements for elderly, frail people with multiple diseases, but many support services today focus on patients with rare or ultra-rare diseases. In addition, there are numerous chronic conditions present in sizable patient communities, even in younger age groups. Expanding home-based healthcare services could therefore have positive effects on bigger patient populations and health systems.
Due to the high degrees of medical complexity, managing comorbidities and multi-morbidities is especially difficult. A patient with heart failure who also requires infusion therapy for cancer poses a problem with timing the administration of the diuretics because the patient must travel to the infusion facility. Home-based care services may develop into a potent catalyst for raising standards of care, enhancing patient satisfaction, and cutting expenses. While there are obvious and distinct benefits for patients and carers with complex and rare diseases, there are also advantages for larger patient populations with more widespread conditions who may face difficulties due to the complexity of their therapy or the effects of comorbidities and multi-disease.
This report tells you how the rare diseases market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2033 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2033, the new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact are discussed in this report.
Segments Covered in the Report
Diseases
- Cancer
- Metabolic Diseases
- Neurological Conditions
- Hematologic Disorders
- Infectious Diseases
- Musculoskeletal Disorders
- Cardiovascular Disorders
- Others
Type
- Non-biologics
- Biologics
End-users
- Specialty Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
Age
- Adult
- Paediatric
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:.
The report also includes profiles and for some of the leading companies in the Rare Diseases Market, 2023 to 2033, with a focus on this segment of these companies' operations.
Leading companies and the potential for market growth
- AbbVie Inc.
- Alexion Pharmaceuticals, Inc. (AstraZeneca)
- Amgen Inc.
- Biogen Inc.
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services, Inc.
- Merck & Co Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceuticals
- Teva Pharmaceuticals
How will the Rare Diseases Market, 2023 to 2033 report help you?
- Revenue forecasts to 2033 for Rare Diseases Market, 2023 to 2033 Market, with forecasts for diseases, type, end-users, and age, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2033 for five regional and 21 key national markets - See forecasts for the Rare Diseases Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 13 of the major companies involved in the Rare Diseases Market, 2023 to 2033.
Key Topics Covered:
1 Report Overview
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increasing Number of Approval Driving Market Growth
3.2.1.2 Robust Pipeline by Major Players
3.2.1.2.1 Pfizer Rare Disease Pipeline
3.2.1.2.2 Sanofi Genzyme Corporation Rare Disease Pipeline
3.2.1.2.3 Novo Nordisk Rare Disease Pipeline
3.2.1.3 Increasing Awareness
3.2.2 Market Restraining Factors
3.2.2.1 High Research and Development Costs
3.2.2.2 High Entry Barriers to Challenge Market Growth
3.2.2.3 Physical Management of Patients Likely to Challenge Market Growth
3.2.3 Market Opportunities
3.2.3.1 Increasing Demand from Emerging Economies
3.2.3.2 Home-based Care Anticipated to Offer Lucrative Growth Prospects
3.2.3.3 Increasing Government Support
3.2.3.4 Rare Diseases Clinical Activity by Indication
3.3 COVID-19 Impact Analysis
3.4 Porter's Five Forces Analysis
3.4.1 Bargaining Power of Buyers (Low)
3.4.2 Bargaining Power of Suppliers (medium)
3.4.3 Threat of Substitutes (Low)
3.4.4 Threat of New Entrants (Low)
3.4.5 Industry Rivalry (High)
4 Rare Diseases Market Analysis by Diseases
5 Rare Diseases Market Analysis by Type
6 Rare Diseases Market Analysis by End-users
7 Rare Diseases Market Analysis by Age
8 Rare Diseases Market Analysis by Region
9 North America Rare Diseases Market Analysis
10 Europe Rare Diseases Market Analysis
11 Asia Pacific Rare Diseases Market Analysis
12 Latin America Rare Diseases Market Analysis
13 MEA Rare Diseases Market Analysis
14 Company Profiles
14.1 AbbVie Inc.
14.2 Alexion Pharmaceuticals, Inc. (AstraZeneca)
14.3 Amgen Inc.
14.4 Biogen Inc.
14.5 F. Hoffmann-La Roche Ltd.
14.6 Johnson & Johnson Services, Inc.
14.7 Merck & Co Inc.
14.8 Novartis AG
14.9 Pfizer Inc.
14.10 Sanofi S.A.
14.11 Takeda Pharmaceuticals
14.12 Teva Pharmaceuticals
14.13 Bristol-Myers Squibb Company
15 Conclusion and Recommendations
For more information about this report visit https://www.researchandmarkets.com/r/2utx38
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
